← Every company
Bristol-Myers Squibb Co Patents
What Bristol-Myers Squibb Co has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
BMY on carbonthat →Filings on file
60
Granted
1
Still pending
59
Filed under
2 names
60 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASEA61K 31/4439, A61P 11/16Filed as Bristol-Myers Squibb Company2026-06-17Aryeh FISCHER | pending |
| LPA1 ANTAGONISTS FOR TREATING INTERSTITIAL LUNG DISEASEA61K 31/4439, A61P 11/00, A61K 31/4418, A61K 31/496Filed as Bristol-Myers Squibb Company2026-06-17Aryeh FISCHER | pending |
| POLYMORPHS OF BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND USES THEREOFA61K 31/5513, C07D 243/24, C07B2200/13Filed as Bristol-Myers Squibb Company2026-04-24Marta Dabros | pending |
| ANTI-CCR8 ANTIBODIES FOR TREATING CANCERC07K 16/2866, A61P 35/00, A61K2039/505, A61K2039/507, A61K2039/545, C07K 16/2818, C07K2317/21, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/41, C07K2317/52, C07K2317/55, C07K2317/565, C07K2317/732, C07K2317/76, C07K2317/92Filed as BRISTOL-MYERS SQUIBB COMPANY2026-04-20RUTH YIN-ZONG LAN | pending |
| ANTI-PSMA ANTIBODIES AND USES THEREOFC07K 16/3069, A61K 47/6869, A61K 47/6817, A61P 35/00, A61K2039/505, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/40, C07K2317/565, C07K2317/92, C12N 15/63Filed as Bristol-Myers Squibb Company2026-04-01Robert James Hoey | pending |
| 2-(4-(2-(7,8-DIMETHYL-[1,2,4]TRIAZOLO[1,5-A] PYRIDIN-6-YL)-3-ISOPROPYL-1H-INDOL-5-YL)PIPERIDIN-1-YL)ACETAMIDE SALT AND CRYSTALLINE FORMS THEREOFC07D 471/04, A61K 31/4545, C07B2200/13, C07C 309/29Filed as Bristol-Myers Squibb Company2026-03-31Prashant Mrityunjaya Sujata Kameshwar | pending |
| 2-(4-(2-(7,8-DIMETHYL-[1,2,4]TRIAZOLO[1,5-A] PYRIDIN-6-YL)-3-ISOPROPYL-1H-INDOL-5-YL)PIPERIDIN-1-YL)ACETAMIDE SALT AND CRYSTALLINE FORMS THEREOFC07D 471/04, A61K 31/4545, C07B2200/13, C07C 309/29Filed as Bristol-Myers Squibb Company2026-03-31Prashant Mrityunjaya Sujata Kameshwar | pending |
| 2-(4-(2-(7,8-DIMETHYL-[1,2,4]TRIAZOLO[1,5-A] PYRIDIN-6-YL)-3-ISOPROPYL-1H-INDOL-5-YL)PIPERIDIN-1-YL)ACETAMIDE SALT AND CRYSTALLINE FORMS THEREOFC07D 471/04, A61K 31/4545, C07B2200/13, C07C 309/29Filed as Bristol-Myers Squibb Company2026-03-31Prashant Mrityunjaya Sujata Kameshwar | pending |
| 2-(4-(2-(7,8-DIMETHYL-[1,2,4]TRIAZOLO[1,5-A] PYRIDIN-6-YL)-3-ISOPROPYL-1H-INDOL-5-YL)PIPERIDIN-1-YL)ACETAMIDE SALT AND CRYSTALLINE FORMS THEREOFC07D 471/04, A61K 31/4545, C07B2200/13, C07C 309/29Filed as Bristol-Myers Squibb Company2026-03-31Prashant Mrityunjaya Sujata Kameshwar | pending |
| SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS AND AZA ANALOGS THEREOFFiled as BRISTOL-MYERS SQUIBB COMPANY2026-03-23ALEXANDRE BELIN | pending |
| TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORSA61P 25/28, C07D 471/04, A61P 17/06, A61P 1/16, A61P 19/02, A61P 1/00, A61P 9/04, A61P 29/00, A61P 1/04, A61K 31/437, A61K 31/444Filed as Bristol-Myers Squibb Company2026-03-23Guanglin Luo | pending |
| SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS AND AZA ANALOGS THEREOFC07D 401/14, A61P 35/00, A61K 31/454, A61K 31/4545, A61K 31/4709, A61K 31/4985, A61K 31/5377, A61K 31/538, A61K 31/5386, A61K 31/55, A61K 31/553, A61K 31/69, A61K 45/06, C07B 59/002, C07D 405/14, C07D 413/14, C07D 417/14, C07D 451/02, C07D 471/04, C07D 487/04, C07D 498/08, C07F 5/025Filed as BRISTOL-MYERS SQUIBB COMPANY2026-03-23ALEXANDRE BELIN | pending |
| ANTI-TREM-1 ANTIBODIES AND USES THEREOFC07K 16/2803, A61K 47/6803, A61P 17/06, A61P 19/02, A61P 1/00, A61P 29/00, A61K2039/505, C07K 16/24, C07K 16/241, C07K2317/32, C07K2317/565, C07K2317/90, C07K2317/92, C12N 15/85Filed as BRISTOL-MYERS SQUIBB COMPANY2026-03-20Achal PASHINE | pending |
| KRAS INHIBITORSC07D 471/04, C07D 519/00, A61P 35/00, A61K 31/519, A61K 31/55, A61K 31/551, A61K 31/553, C07B 59/002, C07D 413/14, C07D 487/04Filed as Bristol-Myers Squibb Company2026-03-17Brian Edward FINK | pending |
| TRIAZOLOPYRIDINYL-THIAZOLYL COMPOUNDS AS KINASE INHIBITORSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-03-16VARNAVAS MOUCHLIS | pending |
| SPIROCYCLIC COMPOUNDS AS KINASE INHIBITORSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-03-16KENNETH M. BOY | pending |
| NOVEL DEGRADER COMPOUNDS AND USES THEREOFFiled as BRISTOL-MYERS SQUIBB COMPANY2026-03-06ANNAPURNA PENDRI | pending |
| LACTAM DERIVED COMPOUNDS AS INHIBITORS OF THE STAT6 PATHWAYFiled as BRISTOL-MYERS SQUIBB COMPANY2026-03-02MICHAEL MANDLER | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24JOHN L. GILMORE | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24JOHN L. GILMORE | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24YANLEI ZHANG | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24JOHN L. GILMORE | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24CHRISTOPHER P. MUSSARI | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24ZHONGHUI LU | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24YANLEI ZHANG | pending |
| NIK COMPOUNDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24LING CHEN | pending |
| MACROCYCLIC INHIBITORS OF NFKB INDUCING KINASEFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-24STEVEN H. SPERGEL | pending |
| TROSPIUM SALTS AND CRYSTAL FORMS THEREOFFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-18VICTOR W. ROSSO | pending |
| NOVEL HYDROLYZABLE LINKER COMPOUNDS FOR ANTIBODY-DRUG CONJUGATES AND USES THEREOFFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-17YAM BAHADUR POUDEL | pending |
| TRICYCLIC SULFONES AS ROR GAMMA MODULATORSC07D 215/36, C07D 221/16, A61P 37/00, A61P 17/06, A61P 25/28, A61P 3/00, A61P 11/06, A61P 37/06, A61P 19/02, A61P 35/02, A61P 37/08, A61P 1/00, A61P 35/00, A61K 31/473, C07D 409/12Filed as BRISTOL-MYERS SQUIBB COMPANY2026-02-06QINGJIE LIU | pending |
| PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDEA61P 29/00, C07C 209/62, C07D 249/08, C07D 403/12, A61P 37/00, A61P 17/06, A61K 31/501, C07B 59/00, C07B 59/001, C07B2200/05, C07B2200/13, C07C 209/00, C07C 211/04, C07C 211/09, C07C 231/08, C07C 233/90, C07C 303/28, C07C 309/73, C07D 237/24, C07C 233/03Filed as Bristol-Myers Squibb Company2026-02-03Ke Chen | pending |
| INDAZOLYL COMPOUNDS AS INHIBITORS OF THE STAT6 PATHWAYFiled as BRISTOL-MYERS SQUIBB COMPANY2026-02-02ZILUN HU | pending |
| BRANCHED PHOSPHOLIPIDSC07F 9/10, C07F 9/106, A61P 35/00, A61K 9/5123, A61K 9/5192, A61K 31/7105, A61K 38/465, A61K 47/24, A61K 48/0091, C12N 15/88, C12N 15/90Filed as BRISTOL-MYERS SQUIBB COMPANY2026-01-29JEFFREY O'BRIEN | pending |
| BRANCHED PHOSPHOLIPIDSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-01-29JEFFREY O'BRIEN | pending |
| POLYMORPHS OF BIS(FLUOROALKYL)-1,4-BENZODIAZEPINONE COMPOUNDS AND USES THEREOFA61K 31/5513, C07D 243/24, C07B2200/13Filed as Bristol-Myers Squibb Company2026-01-29Marta Dabros | pending |
| KRAS INHIBITORSC07D 471/04, A61P 35/00, A61K 31/519, A61K 31/5377, A61K 31/538, A61K 31/5386, A61K 31/553, A61K 31/554, C07D 519/00Filed as Bristol-Myers Squibb Company2026-01-27Brian Edward FINK | pending |
| METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITORG01N 33/57557, A61K 39/3955, C07K 16/2827, A61P 35/00, G01N 33/5751, A61K2039/507, A61K2039/545, C07K 16/2818, C07K2317/21, C07K2317/24, C07K2317/51, C07K2317/76, C07K2317/92, C12Q 1/6886, C12Q 1/708, C12Q2600/106, C12Q2600/158, G01N2333/025, G01N2800/52Filed as Bristol-Myers Squibb Company2026-01-23Demetrios MANEKAS | pending |
| LAG-3 ANTAGONIST THERAPY FOR LUNG CANCERC07K 16/2803, A61P 35/00, A61K 33/243, A61K 31/282, A61K 31/337, A61K 31/519, A61K 39/3955, A61K2039/505, A61K2039/507, A61K2039/545, A61K2039/55, A61K2039/585, A61K2300/00, C07K 16/2818, C07K2317/76Filed as Bristol-Myers Squibb Company2026-01-22Laurence David TOMS | pending |
| CD3 BINDING MOLECULES AND RELATED METHODS AND USESFiled as BRISTOL-MYERS SQUIBB COMPANY2026-01-20LORE K. FLORIN | pending |
| CD19 BINDING MOLECULES INCLUDING CD3- AND CD19- BISPECIFIC T CELL ENGAGERS AND RELATED METHODS AND USESFiled as BRISTOL-MYERS SQUIBB COMPANY2026-01-20RAMAKRISHNA CHANDRAN | pending |
| TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORSFiled as BRISTOL-MYERS SQUIBB COMPANY2026-01-13JIANLIANG SHI | pending |
| TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORSC07D 471/04, A61P 25/28, A61P 29/00, A61K 31/437, A61K 31/444, A61K 31/497, A61K 31/506, C07B 59/002, C07B2200/05Filed as BRISTOL-MYERS SQUIBB COMPANY2026-01-13Jianliang Shi | pending |
| SERUM ALBUMIN-BINDING FIBRONECTIN TYPE III DOMAINSA61K 38/39, C07K 14/78, A61K 47/64, A61K 38/00, C07K 14/765, C07K2319/00, C07K2319/70, C12N 15/62Filed as BRISTOL-MYERS SQUIBB COMPANY2025-12-23Tracy S. MITCHELL | pending |
| LIV1-TLR7/8 IMMUNOMODULATORY CONJUGATE AND USES THEREOFFiled as BRISTOL-MYERS SQUIBB COMPANY2025-12-22SAYUMI YAMAZOE | pending |
| STABILIZED FIBRONECTIN BASED SCAFFOLD MOLECULESC07K 14/78, C40B 40/10, A61K 47/66, A61K 47/64, A61K 47/6435, C07K2318/20, C07K2319/00, G01N 33/58Filed as Bristol-Myers Squibb Company2025-12-18Dasa LIPOVSEK | pending |
| INTERLEUKIN-10 FUSION PROTEINS AND METHODS OF USEFiled as BRISTOL-MYERS SQUIBB COMPANY2025-12-18MARC-WERNER DOBENECKER | pending |
| GENETIC PREDICTORFiled as BRISTOL-MYERS SQUIBB COMPANY2025-12-18EMILY ROSE HOLZINGER | pending |
| NEAR REAL TIME SIALIC ACID QUANTITATION OF GLYCOPROTEINSG01N 33/68, B01D 15/245, B01D 15/3809, B01D 15/424, G01N 30/06, G01N 30/88, G01N 33/58, G01N2030/067, G01N2030/8804, G01N2030/8831Filed as Bristol-Myers Squibb Company2025-12-11Letha CHEMMALIL | pending |
| SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUND AS ANTICANCER AGENTA61K 31/4545, A61K 45/06, C07B 59/002, C07D 401/14Filed as BRISTOL-MYERS SQUIBB COMPANY2025-12-08Godwin Kwame Kumi | pending |
| PROCESS FOR PRODUCING A TETRAHYDROPYRAN-SUBSTITUTED BICYCLIC PYRIMIDINEDIONE COMPOUNDFiled as BRISTOL-MYERS SQUIBB COMPANY2025-12-05THOMAS E. LA CRUZ | pending |
| METHODS FOR INCREASING THE EFFICIENCY OF HOMOLOGY DIRECTED REPAIR (HDR) IN THE CELLULAR GENOMEC12N 15/102, C12N 15/907, C12N2310/20, C12N 9/226, C12N 9/22, C12N 15/113Filed as BRISTOL-MYERS SQUIBB COMPANY2025-12-03John Nathan Feder | pending |
| DOSAGE FORMS FOR TYK2 INHIBITORSA61K 9/146, A61K 9/1652, A61K 31/501, A61P 37/00, A61P 17/06, A61P 37/06, Y02A 50/30, A61P 1/00, A61P 29/00, A61K 9/0053, A61K 9/1694, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/284, A61K 45/06, A61K 47/02, A61K 47/12, A61K 47/26, A61K 47/38Filed as Bristol-Myers Squibb Company2025-12-02Sherif Ibrahim Farag Badawy | 12734169 |
| DOSAGE FORMS FOR TYK2 INHIBITORSA61K 9/146, A61K 9/1652, A61K 31/501, A61P 37/00, A61P 17/06, A61P 37/06, Y02A 50/30, A61P 1/00, A61P 29/00, A61K 9/0053, A61K 9/1694, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2054, A61K 9/284, A61K 45/06, A61K 47/02, A61K 47/12, A61K 47/26, A61K 47/38Filed as Bristol-Myers Squibb Company2025-12-02Sherif Ibrahim Farag Badawy | pending |
| ANTI-CEACAM5 ANTIBODY DRUG CONJUGATESA61K 47/6853, A61K 47/6889, A61P 35/00, A61K 47/68037, C07K 16/3007Filed as Bristol-Myers Squibb Company2025-12-02Nicole VINCENT JORDAN | pending |
| SPIROCYCLIC SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDC07D 491/107, A61K 31/4545, A61K 45/06, C07B 59/002Filed as Bristol-Myers Squibb Company2025-12-01Emily Charlotte CHERNEY | pending |
| ANTI-LRRC15 ANTIBODIES AND USES THEREOFA61K 47/68037, C07K 16/28, A61K 47/6889, A61K 47/6849, A61P 35/00, G01N 33/5759, A61K 45/06, C07K 16/2803, C07K 16/2818, C07K 16/2827, C07K 16/2866, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/34, C07K2317/52, C07K2317/565, C07K2317/77, C07K2317/92Filed as Bristol-Myers Squibb Company2025-11-21Sayumi YAMAZOE | pending |
| ANTI-LRRC15 ANTIBODY DRUG CONJUGATESFiled as BRISTOL-MYERS SQUIBB COMPANY2025-11-21SAYUMI YAMAZOE | pending |
| ANTI-LRRC15 ANTIBODIES AND USES THEREOFFiled as BRISTOL-MYERS SQUIBB COMPANY2025-11-21SAYUMI YAMAZOE | pending |
| ANTI-LRRC15 ANTIBODY DRUG CONJUGATESA61K 47/68037, A61K 47/6843, A61K 47/6889, A61K 47/6851, A61K 47/6849, A61K 47/6879, A61P 35/00, A61K 47/68031, C07K 16/18Filed as Bristol-Myers Squibb Company2025-11-21Sayumi YAMAZOE | pending |
| SUBSTITUTED OXOISOINDOLINYL PIPERIDINE-2,6-DIONE COMPOUNDS AND METHODS OF DEGRADING PROTEINSFiled as BRISTOL-MYERS SQUIBB COMPANY2025-11-21ANDREW P. DEGNAN | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on BMY
Company overviewEverything on BMY in one place, with the price.SEC filingsWhat BMY's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat BMY's own officers and directors buy and sell.Who owns itEvery manager reporting a position in BMY.Funds holding itWhich funds and ETFs hold BMY, and how big a bet.LobbyingWhat BMY spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on BMY's account, and who they worked for.Federal contractsWhat federal agencies pay BMY.